Optimal treatment duration for patients with HCV genotype 1 infection

Journal of Viral Hepatitis

Volumn 19, Issue SUPPL. 1, 2012, Pages 7-13

  Ferenci, P ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

chronic hepatitis C; peginterferon; response guided therapy; ribavirin

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); GENOTYPE; HEPATITIS C; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAPSE; TREATMENT DURATION; VIRAL CLEARANCE; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84855697857     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01522.x     Document Type: Article

References (32)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965. (Pubitemid 32913521)
3. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
4. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43 (3): 425-433. (Pubitemid 41111423)
5. Zeuzem S,. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140 (5): 370-381. (Pubitemid 38268917)
6. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262): 399-401.
7. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461 (7265): 798-801.
8. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138 (7): 2307-2314.
9. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139 (1): 120-129.
10. Stättermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9 (4): 344-350.
11. Craxì A,. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
12. Lee SS, Bain VG, Peltekian K, et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006; 23 (3): 397-408. (Pubitemid 43382020)
13. Marcellin P, Jensen D, Hadziyannis SJ, Ferenci P,. Differentiation of early virologic response (EVR) into RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS). 58th Meeting of AASLD 2007, Boston, MA, USA
14. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J,. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38 (3): 645-652. (Pubitemid 37052151)
15. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135 (2): 451-458.
16. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43 (5): 954-960. (Pubitemid 43724620)
17. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130 (4): 1086-1097.
18. Sakai T, Iino S, Okuno T, et al. High response rates with peginterferon alfa-2A (40KD) (PEGASYS) plus ribavirin (COPEGUS) in treatment-naïve Japanese chronic hepatitis C patients: a randomised, double-blind, multicentre, phase III trial. J Hepatol 2006; 44 (Suppl. 2): S224-S225.
19. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131 (2): 451-460. (Pubitemid 44142452)
20. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006; 131 (4): 1040-1048. (Pubitemid 44515099)
21. Marcellin P, Hadziyannis SJ, Berg T, et al. Virological response at 4 and 12 weeks predict high rates of sustained virological response in genotype 1 patients treated with peginterferon alfa-2a (40KD) plus ribavirin. J Hepatol 2007; 46 (Suppl. 1): S231-S232.
22. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44 (1): 97-103. (Pubitemid 41772522)
23. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47 (1): 43-50. (Pubitemid 351171040)
24. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47 (6): 1884-1893.
25. Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naïve Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47 (10): 1260-1269.
26. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology 2010; 138: 503-512.
27. Pearlman BL, Ehleben C, Saifee S,. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007; 46 (6): 1688-1694.
28. Buti M, Lurie Y, Zakharova NG, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology 2010; 52 (4): 1201-120728.
29. Sanchez-Tapias JM, Ferenci P, Diago M, Romero-Gomez M, Zeuzem S, Berg T,. How can we identify HCV genotype 1 patients who may benefit from an extended treatment duration with peginterferon -2a (40 kD) plus RBV? J Hepatol 2007; 46 (Suppl. 1): S242.
30. Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009; 150 (8): 528-540.
31. Balagopal A, Thomas DL, Thio CL,. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139 (6): 1865-1876.
32. Ferenci P, Formann E, Laferl H, et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection. J Hepatol 2006; 44 (2): 275-282. (Pubitemid 43069208)